This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
KW-3902 - intravenous
Merck & Co., Inc.
Drug Names(s): rolofylline; MK-7418
Description: KW-3902 is an adenosine-A1 receptor antagonist. It acts as a diuretic by counteracting the effects of adenosine at two sites in the kidney (the afferent arteriole and the proximaltubule) where adenosine causes sodium reuptake and, thereby, water retention.
Deal Structure: In August 2003, NovaCardia in-licensed KW-3902 from Kyowa Hakko. Under this agreement, Kyowa Hakko will receive upfront and milestonepayments, and royalties accruing from the sales of commercialized products.
In July 2007, Merck and NovaCardia announced that they had entered into a definitive agreement under which Merck will acquire NovaCardia. Under the agreement, Merck will acquire all of the outstanding equity of NovaCardia for $350 million plus the amount of cash on hand at the time of closing, all of which will be paid in Merck stock based on the average closing stock price on the five days prior to closing of the acquisition.
In September 2007, Merck announced that it had completed the acquisition of NovaCardia. This acquisition adds rolofylline (KW-3902) to Merck's pipeline.
Partners: Kyowa Hakko Kirin Co., Ltd.
KW-3902 - intravenous News
Scrip NovaCardia Inc.
Additional information available to subscribers only: